Real‐world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study
| Autor: | Jane Tighe, Farooq Wandroo, Mark Drummond, Manoj Raghavan, Richard E. Clark, Dragana Milojkovic, Fiona Glen, G. Campbell, Mary Frances McMullin, Sahra Ali, Fiona L Dignan, Brian J. P. Huntly, Pratap Neelakantan, Jacqueline Ryan, Fenella Willis, Sarah J Collington, Jenny Byrne, Louise Fildes, Scott Marshall, Muttuswamy Sivakumaran, Adam J. Mead, Nicholas C.P. Cross |
|---|---|
| Přispěvatelé: | Cross, Nicholas CP [0000-0001-5481-2555], McMullin, Mary Frances [0000-0002-0773-0204], Wandroo, Farooq [0000-0003-3459-3855], Mead, Adam J [0000-0001-8522-1002], Apollo - University of Cambridge Repository |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty chronic myeloid leukaemia medicine.drug_class Cardiovascular risk factors Chronic myeloid leukaemia Tyrosine-kinase inhibitor real-world study 03 medical and health sciences European LeukemiaNet tyrosine kinase inhibitor 0302 clinical medicine Leukemia Myelogenous Chronic BCR-ABL Positive hemic and lymphatic diseases Internal medicine medicine Humans In patient CML management Protein Kinase Inhibitors Retrospective Studies business.industry Disease Management molecular response Retrospective cohort study Imatinib Hematology Middle Aged United Kingdom respiratory tract diseases Treatment Outcome 030220 oncology & carcinogenesis Major Molecular Response Imatinib Mesylate Female business 030215 immunology medicine.drug |
| Zdroj: | BRITISH JOURNAL OF HAEMATOLOGY |
| DOI: | 10.1111/bjh.16733 |
| Popis: | Management of chronic myeloid leukaemia (CML) has recently undergone dramatic changes, prompting the European LeukemiaNet (ELN) to issue recommendations in 2013; however, it remains unclear whether real-world CML management is consistent with these goals. We report results of UK TARGET CML, a retrospective observational study of 257 patients with chronic-phase CML who had been prescribed a first-line TKI between 2013 and 2017, most of whom received first-line imatinib (n = 203). Although 44% of patients required ≥1 change of TKI, these real-world data revealed that molecular assessments were frequently missed, 23% of patients with ELN-defined treatment failure did not switch TKI, and kinase domain mutation analysis was performed in only 49% of patients who switched TKI for resistance. Major molecular response (MMR; BCR-ABL1IS ≤0·1%) and deep molecular response (DMR; BCR-ABL1IS ≤0·01%) were observed in 50% and 29%, respectively, of patients treated with first-line imatinib, and 63% and 54%, respectively, receiving a second-generation TKI first line. MMR and DMR were also observed in 77% and 44% of evaluable patients with ≥13 months follow-up, receiving a second-generation TKI second line. We found little evidence that cardiovascular risk factors were considered during TKI management. These findings highlight key areas for improvement in providing optimal care to patients with CML. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|